1-7 of 7
Crystal Watson, MS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Burden of Hospitalizations Due to Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) in Patients Who Failed First Line Rituximab or Rituximab Plus Chemotherapy Following Solid Organ Transplant (Post-SOT): A Retrospective Chart Review Study of German PTLD Registry

Heiner Zimmermann, MD, Hairong Xu, MD PhD, Arie Barlev, PharmD, Yang Zhang, PhD, Dhanalakshmi Thirumalai, Crystal Watson, MS, Ralf Ulrich Trappe, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 65.
https://doi.org/10.1182/blood-2019-124583
Published: 2019
Journal Articles

The Economic Burden of Short-Term Adverse Events Associated with the CHOP Chemotherapy Regimen in Patients with Lymphoproliferative Disorders in the United States: A Comprehensive Literature Review

Crystal Watson, MS, Arie Barlev, PharmD, Jodie Worrall, Steve Duff, MS, Rachel Beckerman, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5826.
https://doi.org/10.1182/blood-2019-122611
Published: 2019
Journal Articles

Estimating Long-Term Survival in a Cohort of Allogeneic Hematopoietic Stem Cell Transplant Patients

Stephen Palmer, MSc, Casey Quinn, PhD MPhil, Crystal Watson, MS, Arie Barlev, PharmD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3556.
https://doi.org/10.1182/blood-2018-99-113616
Published: 2018
Journal Articles

Treatment Patterns for Patients with Post-Transplant Lymphoproliferative Disorder Who Fail Rituximab after Allogeneic Hematopoietic Stem Cell Transplantation: Findings from a Systematic Literature Review

Hairong Xu, MD PhD, Crystal Watson, MS, Shan Ashton Garib, MA, Anna Forsythe, PharmD, MSc, MBA, Arie Barlev, PharmD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4777.
https://doi.org/10.1182/blood-2018-99-113593
Published: 2018
Journal Articles

A Systematic Literature Review of Real-World Evidence in Post-Transplant Lymphoproliferative Disorder

Hairong Xu, MD PhD, Anna Forsythe, PharmD, MSc, MBA, Arie Barlev, PharmD, Nazia Rashid, PharmD, Crystal Watson, MS
Journal: Blood
Blood (2018) 132 (Supplement 1): 5839.
https://doi.org/10.1182/blood-2018-99-113583
Published: 2018
Journal Articles

Risk of Patients Developing Post-Transplant Lymphoproliferative Disorder within the First Year after an Allogeneic Hemopoietic Stem Cell Transplant, 2011 to 2016: A US Claims Database Analysis

Arie Barlev, PharmD, Hairong Xu, MD PhD, Nicole Fulcher, MA, Crystal Watson, MS, Ila Sruti, MPH, Akshay Sudhindra, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5840.
https://doi.org/10.1182/blood-2018-99-113598
Published: 2018
Journal Articles

Younger Patients Are Impacted By Post-Transplant Lymphoproliferative Disorder: Findings from a Systematic Literature Review of Real-World Evidence

Crystal Watson, MS, Hairong Xu, MD PhD, Anna Forsythe, PharmD, MSc, MBA, Shan Ashton Garib, MA, Arie Barlev, PharmD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5841.
https://doi.org/10.1182/blood-2018-99-113622
Published: 2018